HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DEA cut from Prop 65

This article was originally published in The Rose Sheet

Executive Summary

Diethanolamine will not be listed under Prop 65, California's Office of Environmental Health Hazard Assessment announces March 7. Based upon public comments, OEHHA concludes "it is not clear that the scientific criteria for listing under the authoritative bodies have been met." Office determined sufficient criteria to propose listing the ingredient in 1999 despite attempts by the Cosmetic, Toiletry & Fragrance Association to oppose the listing. Decision coincides with recent recommendation by National Toxicology Program Board of Scientific Counselors subcommittee not to include DEA in NTP's upcoming 11th Report on Carcinogens (1"The Rose Sheet" Nov. 25, 2002, p. 5)...

You may also be interested in...



DEA Exclusion From 11th Report On Carcinogens Advised By NTP Panel

Existing data suggesting diethanolamine may pose a safety risk do not meet National Toxicology Program criteria to be designated a possible human carcinogen, an NTP Board of Scientific Counselors subcommittee concluded at a meeting in Bethesda, Md. Nov. 19

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011043

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel